Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Clearbridge Investments LLC

Clearbridge Investments LLC trimmed its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 10.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 506,089 shares of the company’s stock after selling 60,889 shares during the quarter. Clearbridge Investments LLC’s holdings in Tarsus Pharmaceuticals were worth $41,439,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. TimesSquare Capital Management LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter worth approximately $15,898,000. Citigroup Inc. lifted its holdings in shares of Tarsus Pharmaceuticals by 78.1% in the 3rd quarter. Citigroup Inc. now owns 40,591 shares of the company’s stock worth $2,412,000 after acquiring an additional 17,797 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Tarsus Pharmaceuticals by 5.6% in the 4th quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company’s stock worth $196,476,000 after acquiring an additional 127,470 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in shares of Tarsus Pharmaceuticals by 19.9% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 109,857 shares of the company’s stock worth $8,995,000 after acquiring an additional 18,267 shares during the last quarter. Finally, D.A. Davidson & CO. acquired a new position in shares of Tarsus Pharmaceuticals in the 4th quarter worth approximately $1,493,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Trading Up 3.2%

NASDAQ TARS opened at $61.55 on Wednesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.74 and a quick ratio of 3.71. The firm’s fifty day moving average price is $64.40 and its 200 day moving average price is $70.30. The company has a market capitalization of $2.65 billion, a price-to-earnings ratio of -53.99 and a beta of 0.49. Tarsus Pharmaceuticals, Inc. has a 12 month low of $38.51 and a 12 month high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.24. The firm had revenue of $162.05 million for the quarter, compared to the consensus estimate of $149.60 million. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.19%. On average, sell-side analysts expect that Tarsus Pharmaceuticals, Inc. will post -0.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TARS has been the topic of several recent analyst reports. Lifesci Capital upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 16th. Zacks Research lowered shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. HC Wainwright restated a “buy” rating and issued a $88.00 price objective on shares of Tarsus Pharmaceuticals in a report on Monday, May 4th. Finally, Guggenheim upped their price objective on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $90.67.

Insider Activity at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 11,964 shares of the stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $801,588.00. Following the transaction, the chief executive officer directly owned 33,421 shares of the company’s stock, valued at $2,239,207. This trade represents a 26.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Dianne C. Whitfield sold 4,174 shares of the stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $279,658.00. Following the completion of the transaction, the insider directly owned 35,028 shares in the company, valued at $2,346,876. This trade represents a 10.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 79,391 shares of company stock valued at $5,432,035. Corporate insiders own 9.64% of the company’s stock.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.